Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Comparing Ivermectin Cream 1% (Taro Pharmaceutical Industries, Inc.) To Soolantra™ Cream 1% (US Reference Listed Drug), PrRosiver® Cream 1% (Canadian Reference Product), and Each Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.

NCT07795567 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries, Inc. as lead sponsor.

NCT NCT07795567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07795567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Comparing Ivermectin Cream 1% (Taro Pharmaceutical Industries, Inc.) To Soolantra™ Cream 1% (US Reference Listed Drug), PrRosiver® Cream 1% (Canadian Reference Product), and Each Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 9, 2025
Completion date
June 24, 2026
Enrollment
865 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rosacea